HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

withalongolide A 4,19,27-triacetate

has antineoplastic activity; isolated from Physalis longifolia; structure in first source

Also Known As:

WGA-TA compound

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Cohen, Mark S: 2 articles (12/2019 - 01/2017)
2.	Kuai, Rui: 2 articles (12/2019 - 01/2017)
3.	Moon, James J: 2 articles (12/2019 - 01/2017)
4.	Schwendeman, Anna: 2 articles (12/2019 - 01/2017)
5.	Subramanian, Chitra: 2 articles (12/2019 - 01/2017)
6.	Timmermann, Barbara N: 2 articles (12/2019 - 01/2017)
7.	White, Peter T: 2 articles (12/2019 - 01/2017)
8.	Sanchez, Jaquelyn: 1 article (12/2019)
9.	Wang, Ton: 1 article (12/2019)
10.	Yu, Minzhi: 1 article (12/2019)

Related Diseases

1.	Neoplasms (Cancer) 12/01/2019 - "Treatment with synthetic high-density lipoprotein-encapsulated withalongolide A 4,19,27-triacetate is able to significantly decrease the growth of tumor in mice compared with the control and has better efficacy than the current standard of care, warranting further evaluation as a novel therapeutic agent." 01/01/2017 - "Here, we describe how this natural lipid carrier function of SRB1 can be utilized to improve the tumor-targeted delivery of a novel natural product derivative - withalongolide A 4,19,27-triacetate (WGA-TA) - which has shown potent antitumor efficacy, but poor aqueous solubility. " 12/01/2019 - "In triple negative breast cancer mouse xenografts, treatment with synthetic high-density lipoprotein withalongolide A 4,19,27-triacetate resulted in a 54% decrease in tumor volume compared with the control or with synthetic high-density lipoprotein alone. "
2.	Triple Negative Breast Neoplasms 12/01/2019 - "In triple negative breast cancer mouse xenografts, treatment with synthetic high-density lipoprotein withalongolide A 4,19,27-triacetate resulted in a 54% decrease in tumor volume compared with the control or with synthetic high-density lipoprotein alone. " 12/01/2019 - "Triple negative breast cancers highly overexpress the scavenger receptor B1, and we hypothesize that encapsulation of the novel withalongolide A 4,19,27-triacetate by synthetic high-density lipoprotein will have enhanced efficacy against triple negative breast cancers in vivo. " 12/01/2019 - "The synthetic high-density lipoprotein withalongolide A 4,19,27-triacetate nanoconjugates are potent against triple negative breast cancers and show improved scavenger receptor B1-mediated targeting. "

Related Drugs and Biologics

1.	Nanoconjugates
2.	Scavenger Receptors (Scavenger Receptor)
3.	HDL Lipoproteins
4.	Lipids